KRAS and lung adenocarcinoma: Patient#A was a 69-year-old male, former smoker, treated for a lung adenocarcinoma TTF1+ without EGFR, KRAS, or BRAF mutation or ALK or ROS1 translocation but an expression of 100% of PDL1 on the tumor cell.